|
|
Type of Company:
Type:
|
Company
|
Ownership: |
Publicly Traded (ABUS, NASDAQ) |
Company Size: |
80 Employees In BC (80 Total)
80 In BC (80 Total)
|
Revenue: |
$21.40 Million CAD |
Year Founded: |
1992 |
Sector: |
Biotech/Life Sciences
Biotech/Life Sciences
|
Region: |
Lower Mainland / South Coast
Lower Mainland
|
Tags: |
therapeutics, development, gene silencing, RNAi, genetics
|
Profile Views: |
5,103 Company Profile Views |
|
|
|
Arbutus Biopharma Corporation is a publicly-traded (NASDAQ: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.
In addition to our HBV Assets, we are developing a pipeline of oncology, anti-viral and metabolic programs that leverage our expertise in RNA interference (RNAi) therapeutics and our Lipid Nanoparticle (LNP) technology. |
|
|
Date |
Type |
Amount |
Investors |
Date |
Type |
Amount |
Investors |
|
|
|
|
|
Jun 8, 2017
|
Arbutus Presents HBV Drug Combination Studies at ICAR
|
|
May 10, 2017
|
Arbutus Announces Corporate Update and First Quarter 2017 Financial Results
|
|
Apr 18, 2017
|
Arbutus Injunction Survives Attempted Appeal by Acuitas
|
|
Apr 7, 2017
|
Arbutus Announces Appointment of Daniel Burgess to Board of Directors
|
|
Apr 6, 2017
|
Arbutus Licenses LNP Delivery Technology to Alexion for Use in Single Messenger RNA Product Candidate
|
|
Apr 5, 2017
|
Arbutus Announces Year-End 2016 Financial Results
|
|
Feb 20, 2017
|
Arbutus Is Granted a Pre-trial Injunction Restraining Acuitas From Entering Into Agreements Sublicensing Arbutus LNP
|
|
Jan 11, 2017
|
Arbutus Provides Additional Data from the ARB-1467 Phase II Clinical Trial in HBV Patients
|
|
Dec 20, 2016
|
Arbutus Provides Corporate Update and Announces Third Quarter 2016 Financial Results
|
|
Oct 5, 2016
|
Arbutus Reports Interim Multi-Dose Results from Phase II Clinical Trial of ARB-1467 in Patients with Chronic HBV Infection
|
|
|
1 - 10 of 127 results
|
|
 |
|
|
|
Share This Company Profile |
|
|
|
|
|
|
Disclaimer: Company Profiles in the Tech Directory on T-Net are created, edited and maintained primarily by employees within individual companies, and are subject to continual change without notice and possible errors and/or omissions. Information within the pages of this Tech Directory is of a general nature intended only for informational purposes, and such information should not be relied upon. T-Net does not warrant or guarantee the quality, accuracy or completeness of such information and expressly disclaims liability for any loss, inconvenience or damages (including special, indirect or consequential damages) caused as a result of any errors in, or omissions from, such information. If you see an error, please let us know. Copyright T-Net. All rights reserved.
|
|
News
Events
Tech Careers
Directory
Tech Stocks
T-Net 100
Members
Feedback
About T-Net
Employers
Post Job Listings
Advertise
